Interim report
Page 1
Ли Listed company : Securities code : Representative : Contact : Consolidated Financial Results for the Three Months Ended June 30 , 2026 [ IFRS ] M3 , Inc. 2413 ( Abridged ) FASF MEMBERSHIP August 6 , 2026 Listing : Tokyo Stock Exchange URL : https://corporate.m3.com/en/ Itaru Tanimura , Representative Director Hirofumi Oba , Corporate Officer Tel : + 81-3-6229-8900 Scheduled date to commence dividend payments : Preparation of supplementary materials on financial results : Yes Holding of financial results briefing : Yes ( for analysts and institutional investors ) ( Amounts are rounded to the nearest million yen . ) 1. Consolidated Financial Results for the Three Months Ended June 30 , 2026 ( from April 1 , 2026 to June 30 , 2026 ) ( 1 ) Consolidated Operating Results ( Cumulative ) ( Percentages indicate year - on - year changes . ) Profit attributable to owners of the parent Revenue Operating profit Profit before tax Profit Three Months ended June 30 , 2026 June 30 , 2025 Millions of yen 90,105 86,200 % 4.5 34.2 Millions of yen 18,077 ( 8.6 ) 19,777 17.0 % Millions of yen 18,641 ( 5.3 ) 19,683 4.8 % Millions of yen 10,579 ( 21.8 ) % Millions of yen % 9,074 ( 23.4 ) 13,536 6.2 11,840 5.3 Total comprehensive income Basic earnings Diluted earnings per share per share Three Months ended June 30 , 2026 Millions of yen 14,075 June 30 , 2025 12,403 % 13.5 ( 46.2 ) Yen Yen 13.60 13.59 17.44 17.43 ( 2 ) Consolidated Financial Position Total assets Total equity Equity attributable to owners of the parent Ratio of equity attributable to owners of the parent to total assets Equity per share attributable to owners of the parent As of Millions of yen Millions of yen Millions of yen % Yen June 30 , 2026 634,803 March 31 , 2026 637,396 443,629 446,648 406,122 408,217 64.0 605.97 64.0 608.98 2. Dividends Annual dividends per share First quarter - end Second quarter - end Third quarter - end Fiscal year - end Total Yen Fiscal Year ended March Yen 0.00 Yen Yen Yen 22.00 22.00 31 , 2026 Fiscal Year ending March 31 , 2027 ( Actual ) Fiscal Year ending March 0.00 31 , 2027 ( Forecast ) Note : 1 . 2 . Amendments to forecasts of dividends recently announced : None Dividend forecast for the fiscal year ending March 31 , 2027 is currently undetermined . It is to be determined after consideration of capital needs and condition of cash flow hereafter .
Page 2
3. Consolidated Financial Results Forecasts for the Fiscal Y ear Ending March 31, 2027 (from April 1, 2026 to March 31, 2027) (Percentages indicate year -on-year changes compared to the same period of the previous fiscal year .) Revenue Operating profit Profit before tax Profit Profit attributable to owners of the parent Basic earnings per share Millions of yen % Millions of yen % Millions of yen % Millions of yen % Millions of yen % Yen Six Months ending September 30, 2026 192,000 12.4 37,000 2.8 37,500 2.2 26,000 2.7 24,000 5.7 35.45 Fiscal Year ending March 31, 2027 400,000 13.8 80,000 8.8 81,000 6.2 56,000 3.6 53,000 7.9 78.29 Note: Amendments to forecasts of financial results recently announced: None Notes (1) Significant changes in the scope of consolidation during the period: None (2) Changes in accounting policies and accounting estimates (i) Changes in accounting policies required by IFRS: None (ii) Changes in accounting policies other than item (i) above: None (iii) Changes in accounting estimates: None (3) Number of shares issued (ordinary shares) (i) Total number of shares issued at the end of the period (including treasury shares) As of June 30, 2026 679,124,800 shares As of March 31, 2026 679,120,300 shares (ii) Number of treasury shares at the end of the period As of June 30, 2026 11,695,139 shares As of March 31, 2026 11,695,137 shares (iii) Average number of shares outstanding during the period Three Months ended June 30, 2026 667,428,932 shares Three Months ended June 30, 2025 678,863,207 shares • Review of this financial report by certified public accountants or an audit firm: None • Proper use of financial results forecasts and other special matters (1) Disclaimer about forward-looking statements The forward-looking statements herein are based on information available to the Company and on certain assumptions deemed to be reasonable at the date of publication of this document. They are not intended as the Company’s commitment to achieve such forecasts, and actual results may differ significantly due to various factors. (2) Supplementary materials on financial results Supplementary materials on financial results will be posted on our website on Thursday, August 6, 2026.
Page 3
- 1 - 1. Overview of Financial Results, etc. (1) Overview of Financial Results for the Three Months Ended June 30, 2026 In Japan, we provide various services designed for healthcare professionals, centered on our website at m3.com with a membership of more than 350,000 physicians. In Medical Platform segment, we offer a wide menu of services on the platform at m3.com, catering to various agendas and purposes of our clients. The services include MR-kun family services, which allow its registered physicians to proactively receive continuous and frequent information, marketing research services leveraging our panel of member healthcare professionals, and marketing support services for pharmaceutical companies to resolve fundamental drug-related challenges by utilizing the synergy of the M3 Group’s diverse data assets and technologies including AI. In addition, our group companies provide a variety of services for medical institutions, including AI-enabled electronic medical records (EMR), consultation support system, and a platform that allow s for access to various medical AI centered on diagnostic imaging support, as well as external business succession support services for private practitioners using the panel of member physicians of m3.com. We also provide employee benefits services through EWEL,Inc., our new subsidiary acquired in April 2025, as part of the White Jack Project, aimed at maintaining people’s health from the pre-onset stage. In Evidence Solution segment, our group companies operate businesses serving as the following organizations: CRO that supports clinical development operations and large-scale clinical research; SMO that supports the management and operations of overall activities at clinical trial sites; and PRO that provides support for recruiting participants and carrying out peripheral operations necessary to conduct clinical development and clinical research. In Career Solution segment, M3 Career, Inc. primarily provides job search and placement support services to physicians and pharmacists. Site Solution segment provides services that assist medical institutions with their operations. Patient Solution segment provides patient support services targeting hospitalized patients, nursing facility users, and so forth through offerings including “CS (Care Support) Set.” It also provides consumer -facing services, such as AskDoctors at <https://www.AskDoctors.jp /> (available in Japanese only). On this website, the member physicians of m3.com will answer questions from public users about health and diseases. Furthermore, M3 Education, Inc. provides medical and welfare professional education such as preparatory services for national examinations. The M3 Group operates websites for healthcare professionals and has panels of physicians around the world, including Japan, the U.S., Europe, China, and South Korea, and the total number of healthcare professionals who have signed up for the websites and /or participated in the panels is now more than 7 million. Overseas segment provide s global marketing research services u sing the panels of physicians, and it also offers services for pharmaceutical companies, career-related services focused on physicians, and others, primarily in the U.S. and Europe. Additionally, our offerings include clinical trial support services in North America, pharmaceutical database services in France, Germany, and Spain through the V IDAL Group, and the provision of SaaS -based EMR system “Weda” and other software for clinics primarily in France . We steadily expand business in other regions with a focus on Asia, especially India and South Korea, as well. Consolidated financial results for the three months ended June 30, 2026 are as below. (Millions of yen, unless otherwise stated) Three Months ended June 30, 2025 (April 1, 2025 to June 30, 2025) Three Months ended June 30, 2026 (April 1, 2026 to June 30, 2026) Year-on-year change (Reference) Fiscal Year ended March 31, 2026 (April 1, 2025 to March 31, 2026) Revenue 86,200 90,105 +3,905 +4.5% 351,363 Operating profit 19,777 18,077 (1,700) (8.6%) 73,547 Profit before tax 19,683 18,641 (1,042) (5.3%) 76,276 Profit 13,536 10,579 (2,957) (21.8%) 54,046
Page 4
- 2 - Consolidated financial results by segment (Millions of yen, unless otherwise stated) Three Months ended June 30, 2025 (April 1, 2025 to June 30, 2025) Three Months ended June 30, 2026 (April 1, 2026 to June 30, 2026) Year-on-year change Medical Platform Segment revenue 25,274 25,585 +311 +1.2% Segment profit (loss) 8,981 8,872 (109) (1.2%) Evidence Solution Segment revenue 6,219 5,691 (528) (8.5%) Segment profit (loss) 1,314 879 (435) (33.1%) Career Solution Segment revenue 8,280 7,999 (281) (3.4%) Segment profit (loss) 3,665 3,597 (68) (1.8%) Site Solution Segment revenue 12,996 14,159 +1,163 +9.0% Segment profit (loss) 727 15 (712) (97.9%) Patient Solution Segment revenue 13,422 14,752 +1,330 +9.9% Segment profit (loss) 451 750 +299 +66.2% Overseas Segment revenue 20,725 22,748 +2,023 +9.8% Segment profit (loss) 4,852 4,615 (237) (4.9%) Other Emerging Businesses Segment revenue 493 480 (12) (2.5%) Segment profit (loss) 252 133 (119) (47.3%) Adjustment Segment revenue (1,208) (1,308) － － Segment profit (loss) (466) (784) － － Total Revenue 86,200 90,105 +3,905 +4.5% Operating profit (loss) 19,777 18,077 (1,700) (8.6%) 1) Medical Platform Segment revenue amounted to 25,585 million yen, up 1.2% year on year , with segment profit of 8,872 million yen, down 1.2% year on year . This is attributable t o a decline in revenue from the pharmaceutical marketing support business, a high -margin area, while businesses such as digitalization support for medical practices showed solid performance. 2) Evidence Solution Segment revenue amounted to 5,691 million yen, down 8.5% year on year, with segment profit of 879 million yen, down 33.1% year on year. This is attributable to the absence of the contribution from relatively high-margin projects and large-scale projects recorded in the same period of the previous fiscal year. 3) Career Solution Segment revenue amounted to 7,999 million yen, down 3.4% year on year, with segment profit of 3,597 million yen, down 1.8% year on year. This is mainly attributable to a decline in revenue from job search and placement support services for physicians and pharmacists. 4) Site Solution Segment revenue amounted to 14,159 million yen, up 9.0% year on year. This is attributable to the steady growth across businesses, particularly in the medical institution business and the hospice business. Segment profit amounted to 15 million yen, down 97.9% year on year. This is mainly attributable to an increase in upfront investments for new facility openings in the U.S. business and in-home nursing business. 5) Patient Solution Segment revenue amounted to 14,752 million yen, up 9.9% year on year, with segment profit of 750 million yen, up 66.2% year on year. This is mainly attributable to the growing user base driven by new contracts for CS Set and the change in accounting treatment for original patient gowns from the fourth quarter of the previous fiscal year.
Page 5
- 3 - 6) Overseas Segment revenue amounted to 22,748 million yen, up 9.8% year on year. This is attributable to the revenue growth across regions driven by positive foreign exchange impact from the year -on-year trend of yen depreciation. Segment profit amounted to 4,615 million yen, down 4.9% year on year , mainly due to the impact of proactive upfront investments. 7) Other Emerging Businesses Segment revenue amounted to 480 million yen, down 2.5% year on year, with segment profit of 133 million yen, down 47.3% year on year. Combining all of the above, revenue of the M3 Group for the three months ended June 30, 2026 amounted to 90,105 million yen, up 4.5% year on year, with operating profit of 18,077 million yen, down 8.6% year on year, profit before tax of 18,641 million yen, down 5.3% year on year, and profit of 10,579 million yen, down 21.8% year on year. ------------------------------------------------------------------------------------------------------------------------------------------------------------------ Disclaimer: This document is a translation of the original Japanese version. The original Japanese version was prepared and disclosed by the Company in accordance with International Financial Reporting Standards. This document does not contain or constitute any guarantee and the Company will not compensate for any losses or damages arising from interpretations or actions taken based on this document. In the case of any discrepancies between the Japanese original and this document, the Japanese original is assumed to be correct.